Good Molecules lands Aria Growth Partners investment at ~$100M in annual sales
What's the deal? Aria Growth Partners, a consumer-focused growth equity firm, has invested in Good Molecules, an affordable, ingredient-led skincare brand. Neither party commented on the deal terms, but industry sources estimate Good Molecules is profitable and generating roughly $100M in annual sales.
The investment adds to an Aria portfolio that already includes skincare brands The Inkey List and Ultra Violette. The firm, founded in 2020 by Jackie Dunklau (formerly of CAVU Venture Partners) and Trevor Nelson (formerly of Alliance Consumer Growth), typically writes $10M to $40M-plus cheques for minority stakes in companies doing $10M to over $100M in revenue.
Aria closed its second fund at $152M last year and manages nearly $250M in assets. Its previous portfolio companies LesserEvil and Hero Cosmetics exited to The Hershey Co. and Church & Dwight for $750M and $630M, respectively.
Why now? Science-backed skincare is one of beauty's hottest investment categories. XRC Ventures found that science-backed brands command 5X to 6X revenue multiples — about 20% higher than peers without strong scientific positioning.
The deal wave is broad. Recent transactions include L'Oréal's acquisition of Medik8, Bansk's majority stake in Byoma, and Prelude Growth Partners' investment in OneSkin. Market research firm Circana calls skincare a "steady growth engine," with first-quarter US sales up 7% in prestige and 8% in mass.
Good Molecules has been gaining ground fast. It cracked the top 20 skincare brands at Target in Q1, and shopper insights firm Sorcea Labs ranked it the fifth most popular skincare brand on American college campuses — behind CeraVe, La Roche-Posay, The Ordinary, and Paula's Choice, but ahead of Clinique, Neutrogena, Rhode, and Glow Recipe.
What could go wrong? The affordable skincare space is crowded and getting more competitive. Moving price or positioning in any direction risks colliding with clinical brands, drugstore staples, or celebrity-backed lines.
"Good Molecules is a Goldilocks brand," said Jadon Wyant, chief executive officer of Sorcea Labs. "Move the price up, and you're competing with clinical brands. Move it down, and you're on a shelf next to drugstore products. Lean heavily on status, and you lose to celebrity-backed brands."
The signal: Aria's thesis is clear — masstige skincare built on active ingredients, efficacy, and value still has room to run. Its portfolio bet on The Inkey List (forecast to hit $200M in retail sales this year) and now Good Molecules suggests the firm sees a repeatable playbook in the category. For investors, affordable science-backed skincare remains one of beauty's most bankable bets.
Read more: beautyindependent.com
